GlassScriptPhysician profile
Rory Michael Shallis
NPI 1669884383
$28,701.74
in general payments reported to CMS, 2019-2025
10 companies · $4,956 in 2025
The $4,956 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.95 · 2020: $195 · 2021: $1,000 · 2022: $2,076 · 2023: $11K · 2024: $9,213 · 2025: $4,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $4,384 · Travel and Lodging: $3,412 · Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,649.67 |
| Honoraria | $4,384.00 |
| Travel and Lodging | $3,412.38 |
| Food and Beverage | $884.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $9,644.43 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $9,613.15 | 2023-2024 | Rezlidhia, Tavalisse |
| Geron Corporation | $4,553.29 | 2025 | Imetelstat, Rytelo |
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 2022 | |
| Beigene, LTD. | $1,116.67 | 2023 | Brukinsa |
| Vertex Pharmaceuticals Incorporated | $880.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $403.00 | 2025 | |
| Amgen INC. | $294.90 | 2019-2020 | |
| Tg Therapeutics, INC. | $120.30 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rory Shallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.